Your browser is no longer supported. Please, upgrade your browser.
BCRX [NASD]
BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.76 Insider Own0.60% Shs Outstand176.52M Perf Week14.93%
Market Cap1.59B Forward P/E- EPS next Y-0.95 Insider Trans-9.44% Shs Float175.06M Perf Month12.68%
Income-124.90M PEG- EPS next Q-0.23 Inst Own74.00% Short Float17.68% Perf Quarter159.19%
Sales53.50M P/S29.77 EPS this Y4.00% Inst Trans1.70% Short Ratio4.58 Perf Half Y89.73%
Book/sh0.19 P/B48.63 EPS next Y3.10% ROA-71.10% Target Price11.22 Perf Year215.36%
Cash/sh0.83 P/C11.11 EPS next 5Y19.90% ROE-328.70% 52W Range1.58 - 9.35 Perf YTD24.03%
Dividend- P/FCF- EPS past 5Y-6.80% ROI-84.10% 52W High-1.18% Beta2.93
Dividend %- Quick Ratio1.40 Sales past 5Y29.10% Gross Margin92.20% 52W Low484.81% ATR0.54
Employees140 Current Ratio1.50 Sales Q/Q238.90% Oper. Margin- RSI (14)75.20 Volatility6.49% 6.44%
OptionableYes Debt/Eq2.26 EPS Q/Q23.30% Profit Margin- Rel Volume0.72 Prev Close9.06
ShortableYes LT Debt/Eq0.80 EarningsNov 05 BMO Payout- Avg Volume6.76M Price9.24
Recom2.10 SMA2018.13% SMA5042.66% SMA20096.66% Volume4,878,995 Change1.93%
Sep-29-20Resumed JP Morgan Overweight $7
Jun-17-20Initiated BTIG Research Neutral
May-05-20Upgrade Barclays Equal Weight → Overweight $7
Nov-15-19Upgrade BofA/Merrill Neutral → Buy $5 → $4
May-24-19Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4.50
Nov-16-18Resumed Piper Jaffray Overweight $15
Aug-08-18Resumed JP Morgan Overweight $9
Jul-17-18Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18Initiated Seaport Global Securities Neutral
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-20-17Initiated Barclays Equal Weight $6
Sep-15-17Initiated RBC Capital Mkts Sector Perform $6
Sep-06-17Upgrade JP Morgan Neutral → Overweight
Sep-06-17Upgrade Jefferies Hold → Buy
Feb-16-17Initiated Ladenburg Thalmann Buy $11
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated FBR Capital Outperform $18 → $6
Feb-09-16Downgrade Needham Buy → Hold
Feb-09-16Downgrade JP Morgan Overweight → Neutral
Jan-07-21 07:00AM  
Jan-06-21 07:00AM  
Dec-23-20 10:15AM  
10:12AM  
07:13AM  
Dec-22-20 11:42AM  
07:00AM  
Dec-21-20 10:01AM  
07:00AM  
Dec-18-20 08:28PM  
Dec-16-20 07:00AM  
Dec-11-20 07:00AM  
Dec-09-20 01:10PM  
09:56AM  
Dec-08-20 11:50PM  
Dec-07-20 08:45AM  
08:40AM  
Dec-06-20 10:00AM  
Dec-04-20 12:59PM  
12:25PM  
10:02AM  
09:00AM  
Dec-03-20 08:45PM  
11:59AM  
10:34AM  
Dec-01-20 04:15PM  
Nov-30-20 07:00AM  
Nov-20-20 07:00AM  
Nov-13-20 07:59AM  
07:02AM  
07:00AM  
Nov-12-20 07:00AM  
Nov-07-20 08:01AM  
Nov-05-20 11:01PM  
09:25AM  
07:00AM  
Nov-02-20 04:15PM  
Oct-30-20 08:15AM  
Oct-29-20 12:35PM  
Oct-28-20 07:31AM  
07:00AM  
Oct-22-20 04:15PM  
07:00AM  
Oct-07-20 08:34AM  
Oct-05-20 04:15PM  
Sep-30-20 07:00AM  
Sep-28-20 03:09PM  
Sep-22-20 07:25AM  
Sep-08-20 07:00AM  
Sep-03-20 04:15PM  
07:00AM  
Aug-31-20 09:29AM  
07:00AM  
Aug-17-20 11:41AM  
Aug-13-20 01:48PM  
Aug-11-20 08:54AM  
Aug-06-20 09:55AM  
07:00AM  
Aug-04-20 07:00AM  
Aug-03-20 11:19AM  
07:00AM  
Jul-23-20 07:00AM  
Jul-18-20 07:16PM  
Jul-15-20 11:35AM  
Jul-07-20 02:43PM  
11:57AM  
11:30AM  
Jul-02-20 07:00AM  
Jun-18-20 08:53AM  
Jun-15-20 07:43AM  
Jun-10-20 02:00PM  
Jun-09-20 04:15PM  
Jun-08-20 03:40PM  
Jun-06-20 03:01AM  
03:00AM  
Jun-02-20 07:15AM  
Jun-01-20 04:01PM  
May-28-20 04:15PM  
May-27-20 11:35PM  
06:21PM  
04:01PM  
May-26-20 07:00AM  
12:36AM  
May-19-20 03:18PM  
May-18-20 02:47PM  
09:30AM  
09:21AM  
May-15-20 07:53AM  
07:00AM  
May-13-20 11:30AM  
May-11-20 02:45PM  
May-07-20 01:07PM  
07:00AM  
May-06-20 07:31PM  
08:55AM  
07:42AM  
07:00AM  
May-05-20 07:00AM  
May-04-20 04:15PM  
Apr-29-20 01:17PM  
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stonehouse Jon PPresident & CEODec 15Option Exercise4.15134,278557,254918,364Dec 17 04:20 PM
Stonehouse Jon PPresident & CEODec 15Sale8.32134,2781,117,193784,086Dec 17 04:20 PM
Barnes Alane PSenior VP, Chief Legal OfficerDec 11Option Exercise4.1513,74157,025121,802Dec 15 05:35 PM
Barnes Alane PSenior VP, Chief Legal OfficerDec 11Sale7.9613,741109,378108,061Dec 15 05:35 PM
Barnes Alane PSenior VP, Chief Legal OfficerDec 04Option Exercise4.1513,74157,025121,802Dec 08 04:12 PM
Barnes Alane PSenior VP, Chief Legal OfficerDec 04Sale6.2313,74185,606108,061Dec 08 04:12 PM
Doyle AnthonyChief Financial OfficerAug 11Buy4.0854,000220,32054,000Aug 12 04:31 PM